ArticleThe Journal of infectious diseases2026
Persistent T Cell Immunity Following Nipah Virus Infection: Evidence From Malaysian Survivors.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A single-cycle, recombinant VSV platform Nipah vaccine cross-protects against Hendra virus in nonhuman primates.PLoS pathogens · 2026Article
- Viral RNA persistence and long-term consequences following acute infection with Risk Group 4 zoonotic viruses.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Nipah virus (NiV) induces strong humoral immunity, but the durability of NiV-specific memory T-cell responses remains unclear. We characterized cellular immunity approximately 25 years after infection in 4 survivors of the 1998 Malaysian outbreak. PBMCs were stimulated with overlapping peptide mini-pools spanning the NiV fusion (NiV-F) and attachment (NiV-G) glycoproteins, and responses were assessed using enzyme-linked immune absorbent spot and intracellular cytokine staining. Durable cytokine-producing T-cell responses were detected, with immunodominant epitopes in the NiV-G ectodomain. Survivors with neurological sequelae exhibited stronger T-cell responses and cognitive impairment, highlighting persistent cellular immunity decades after infection with implications for vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.